The Latest Breaking News from FDA

Dr Art Van Zee set out in the early 2000s to tell anyone who would listen how a powerful opioid was destroying lives. Two decades later, he’s still in disbelief

The president has made big promises and held the line against legal challenges, but activists say he could be doing more

The distributors have been notified and provided with instructions for the return of all recalled products.

Google recently added support for taking your body's temperature with the Pixel 8 Pro, and this is how the feature works.

The development of orphan medications, innovative biotech equipment, personalized medicine, and strong government support are all contributing to the biotech industry's upward trajectory. Thus, lucrative biotech stocks Vertex Pharmaceuticals (VRTX), Innoviva (INVA), and Organogenesis Holdings (ORGO) could be ideal additions to your portfolio right now. Read more….

This news report highlights Senator Chuck Schumer's call for a federal shutdown on Zen nicotine pouches due to concerns over its impact on young people.

In the swiftly progressing arena of biotechnology, technological advancements, increasing merger and acquisition maneuvers, and developing product pipelines are driving significant expansion in this sector. The sector's strong potential is further reinforced by a steady demand, ensuring its sustenance. Given this backdrop, let’s analyze whether or not biotech stocks Illumina…

A slew of features will be rolling out this morning for Pixel users as part of the January 2024 feature drop. This includes a fully realized temperature sensor, Magic Compose, and more.

The biotech industry is well poised to flourish, buoyed by its commitment to innovation and potential for groundbreaking discoveries. Thus, investing in the shares of three fundamentally solid biotech companies, Foghorn Therapeutics (FHTX), Jazz Pharmaceuticals (JAZZ), and Gilead Sciences (GILD), might be prudent. Continue reading….

A new study suggests a promising blood test that could diagnose Alzheimer's disease accurately and early, potentially revolutionizing dementia care.

They're pioneering a new model of care that will allow for one-stop, same-day access to mifepristone — no appointment necessary.